NICE GUIDANCE HEPATITIS B AND C: WAYS TO OFFER AND PROMOTE TESTING

3rd Meeting of the Programme Development Group

Thursday 28th July 2011

Dee, NICE Offices, Manchester

Attendees:	 Programme Development Group (PDG) Members: Will Irving (Chair), Neil Connelly, James Windsor, Opal Greyson, Kylie Reed, April Wareham, Emily Kam-Yin Lam, Salim Khakoo, Danny Morris, Cristina Osorio, Deirdre Kelly, Kate Drysdale, Jeremy Jones, Erika Duffell <i>NICE:</i> Antony Morgan, Kay Nolan, Alastair Fischer, Victoria Axe, Hilary Chatterton, Paul Levay (arrived at 10.30) <i>Contractors:</i> Lisa Jones, Amanda Atkinson, Natasha Martin, Mary Ramsey (arrived at 12pm), Anjan Ghosh (arrived at 12pm), Alec Miners (arrived at 12pm),
Apologies:	PDG Members: Richard Grieve, Nat Wright, Vijay Anand, Matt Hickman, Helen Wilks, Daniela De Angelis Contractors: Peter Vickerman

Author	Victoria Axe
File Ref	Hepatitis PDG 2 – Draft Minutes
Version	Draft
Audience	PDG members, NICE team, the public (via web publication)

Item		Action
1. Welcome, Introductions and focus of the Meeting	The Chair welcomed the group to the second PDG meeting. The Chair informed the group that the usual chair, Matt Hickman, had given apologies for the meeting and therefore Will Irving would be performing the role of chair. The Chair introduced Jeremy Jones as a new PDG member. The PDG members introduced themselves.	
2. Declarations of Interests and notes of the last meeting	 The Chair asked the PDG to declare any conflicts of interest. Opal Greyson declared a non-personal pecuniary interest - she will be receiving £7000 from Amnesty International. April Wareham declared a personal non-pecuniary interest - she will be a member of the Board for the Substance Misuse Management General Practice. Kate Drysdale declared a personal non-pecuniary interest - she recently took part in a day's consultancy for MSD. The minutes of the last meeting were consulted and suggested amendments recorded. 	
3. Where we are now – meeting overview	Antony Morgan gave a presentation on an overview of today's meeting and the suggested process. This included the meeting objectives, reviewing the evidence and drafting recommendations. AM asked the PDG to consider the idea of having a call for evidence. AM brought certain frameworks for drafting recommendations to the PDGs attention. Action – AM to circulate his slides to the PDG	АМ
4. NICE clinical guideline on Hepatitis B	Kay Nolan gave an overview on the NICE Clinical Guideline Hepatitis B draft scope suggesting that this will help to compliment Pubic Health's guidance. On the back of the Clinical Guideline a Quality Standard will be produced. It has been suggested that the work this PDG does will be fed into this quality standard. It was requested by the PDG that NICE Public Health also have a quality standard. Action: AM to discuss with the Director of Public Health the suggestion of NICE Public Health creating a Quality Standard	АМ

	Emily Kam-Yin Lam told the PDG that she is applying for a role on the Guideline Development Group on Hepatitis B.	
	The suggestion was made that members of the GDG be invited to attend the PDG meetings.	
	Action: AM will invite the chair of the GDG to the next PDG meeting	AM
	The Chair suggested that the Joint Committee of Vaccination and Immunisation discuss vaccinations for Hepatitis B and C and therefore vaccinations are outside this remit and neither Public Health nor Clinical Guidelines will be discussing this.	
5. Existing public health recommendati ons	Hilary Chatterton thanked the PDG for their responses to her previous email. HC gave an overview of the responses received.	
	The Chair commented on whether these recommendations were useful. However, it was suggested that they helped to focus on the areas that were relevant and it will be useful to revisit these recommendations at future PDG meetings.	
6. Qualitative Review – Presentation and Questions	Lisa Jones and Amanda Atkinson gave separate presentations on the Qualitative review for Hepatitis B and C. LJ revisited the questions from the scope and both discussed the key themes which were as follows:	
	 Knowledge, beliefs and practices Views, Experiences and attitudes Barriers to testing Facilitators to testing Opportunities for changing behaviour 	
	LJ and AA gave a summary of their findings and discussed the research gaps.	
	The PDG were invited to ask questions.	
7. Small group discussions on qualitative review	The chair suggested that discussions occurred as a plenary group as opposed to small groups. The outcome of these discussions was to form recommendations, think about what gaps there are in the information and what further information is needed, and to consider equity issues.	
	The PDG were reminded that equity issues should be considered at every point in the production of this guidance.	

·· ·		
8. Feedback on discussions	 The PDG started to discuss areas for recommendations which included: Raising awareness among professionals Raising awareness among those with increased risk 	
	Action: NICE team to draft recommendations for presentation at the next PDG meeting	NICE Team
9. Hepatitis B Immunisation Programmes	Mary Ramsey gave an overview on behalf of Health Protection Agency on work carried out to consider future policy options relating to universal vaccination for adolescents and children.	
	MR also gave a presentation on HPA data available for informing testing of hepatitis B and C.	
	The data shown will soon be available on the HPA website.	
	Action: Antony to send presentation to PDG members	AM
10. Economic Modelling	Alastair Fischer updated the PDG on the economics subgroup meeting from 16 th June.	
	AF informed the whole PDG that they are welcome to participate in the economics subgroups.	
	Natasha Martin presented a dynamic model of Hepatitis C testing among Injecting Drug Users.	
	Alec Miners and Anjan Ghosh presented a draft algorithm for the economic model on Hepatitis B.	
11. Questions and discussion	A number of questions were posed by the PDG to the London School of Hygiene and Tropical Medicine which involved.	
	Age range included in the model population (HCV-	
	 IDU) Sequence of disease progression (HCV –IDU) Clarified that presence of core antibody at first test reduced need for vaccination (HBV) 	
12. Mapping Review update	Lisa Jones gave a presentation on the practice survey of activities and interventions that aim to raise awareness among, and/or engage with, groups who are at an increased risk of hepatitis B and C infection. LJ mentioned that they will continue to update NICE with responses to their online questionnaire.	
	Action: NICE Team to send round the slides from this presentation with the online questionnaire web link.	NICE Team
	Action: If the PDG are aware of any appropriate groups	

	who could fill in the questionnaire they should send these groups the web link.	PDG
13. Next steps	AM confirmed that the next meeting with take place on the 15 th September and the mailing of the papers will be on the 2 nd September.	
	During the next meeting the PDG will be considering the mapping review and effectiveness review. The NICE Project Team will feed back on draft recommendations following the discussions today.	
	AM will ask the Clinical Guidelines Chair to attend the next PDG.	
	AM asked the PDG for their suggestions on potential experts to be invited to future PDG meeting.	
	AM had received feedback from some members that a mixture of plenary and small group discussions would be useful for future meetings depending on the task.	
	Action: PDG to email <u>antony.morgan@nice.org.uk</u> or <u>kay.nolan@nice.org.uk</u> with suggestions of experts	PDG members
14. Close	The meeting closed at 15.55pm	

Next meeting

PDG 4: 15th September 2011, Floor 24, City Tower, Manchester Papers to be emailed 2nd September, 2011